159 related articles for article (PubMed ID: 26535588)
21. Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study.
Hassan MO; Duarte R; Mabayoje VO; Dickens C; Lasisi AO; Naicker S
BMC Nephrol; 2020 Oct; 21(1):436. PubMed ID: 33066744
[TBL] [Abstract][Full Text] [Related]
22. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
Hamzah L; Jose S; Booth JW; Hegazi A; Rayment M; Bailey A; Williams DI; Hendry BM; Hay P; Jones R; Levy JB; Chadwick DR; Johnson M; Sabin CA; Post FA
J Infect; 2017 May; 74(5):492-500. PubMed ID: 28130143
[TBL] [Abstract][Full Text] [Related]
23. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Decloedt EH; Lesosky M; Maartens G; Joska JA
AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
[TBL] [Abstract][Full Text] [Related]
24. Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.
Boyd A; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Plaisier E; Lacombe K
Antivir Ther; 2017; 22(1):31-42. PubMed ID: 27553871
[TBL] [Abstract][Full Text] [Related]
25. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
26. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
27. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
[TBL] [Abstract][Full Text] [Related]
28. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
29. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.
De Waal R; Cohen K; Fox MP; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
J Int AIDS Soc; 2017 Apr; 20(1):21317. PubMed ID: 28406595
[TBL] [Abstract][Full Text] [Related]
30. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
31. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Pradat P; Le Pogam MA; Okon JB; Trolliet P; Miailhes P; Brochier C; Maynard M; Bailly F; Zoulim F; Cotte L
J Viral Hepat; 2013 Sep; 20(9):650-7. PubMed ID: 23910650
[TBL] [Abstract][Full Text] [Related]
32. Discontinuation of tenofovir due to nephrotoxicity: insight into 12 years of clinical practice.
Matłosz B; Kowalska JD; Bąkowska E; Firląg-Burkacka E; Vassilenko A; Horban A
Przegl Epidemiol; 2019; 73(2):249-255. PubMed ID: 31385682
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
Casado JL; Bañón S; Santiuste C; Serna J; Guzman P; Tenorio M; Liaño F; del Rey JM
AIDS; 2016 Jan; 30(2):231-9. PubMed ID: 26684820
[TBL] [Abstract][Full Text] [Related]
34. ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment.
Cheli S; Baldelli S; De Silvestri A; Fusi M; Minisci D; Gervasoni C; Cattaneo D; Clementi E; Meraviglia P; Montrasio C
Pharmacogenomics J; 2021 Oct; 21(5):586-593. PubMed ID: 33850298
[TBL] [Abstract][Full Text] [Related]
35. Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.
Lapadula G; Bernasconi DP; Casari S; Maggiolo F; Cauda R; Di Pietro M; Ladisa N; Sighinolfi L; Dal Zoppo S; Sabbatini F; Soria A; Pezzoli C; Mondi A; Costarelli S; Valsecchi MG; Torti C; Gori A;
PLoS One; 2016; 11(9):e0162320. PubMed ID: 27632369
[TBL] [Abstract][Full Text] [Related]
36. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
De Beaudrap P; Diallo MB; Landman R; Guèye NF; Ndiaye I; Diouf A; Kane CT; Etard JF; Girard PM; Sow PS; Delaporte E;
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1221-7. PubMed ID: 20854202
[TBL] [Abstract][Full Text] [Related]
37. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia.
Deckert A; Neuhann F; Klose C; Bruckner T; Beiersmann C; Haloka J; Nsofwa M; Banda G; Brune M; Reutter H; Rothenbacher D; Zeier M
PLoS One; 2017; 12(9):e0184766. PubMed ID: 28931037
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.
Peyriere H; Cournil A; Casanova ML; Badiou S; Cristol JP; Reynes J
PLoS One; 2015; 10(11):e0142491. PubMed ID: 26571117
[TBL] [Abstract][Full Text] [Related]
39. Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management.
Boucquemont J; Lawson-Ayayi S; Rigothier C; Bonnet F; Proust-Lima C; Neau D; Greib C; Miremont-Salamé G; Dabis F; Dupon M; Dauchy FA;
Nephron; 2017; 136(3):211-220. PubMed ID: 28445881
[TBL] [Abstract][Full Text] [Related]
40. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]